Cantargia presents new clinical data at AACR 2023 strongly supporting nadunolimab development in pancreatic cancer
April 17, 2023Business Services
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today presented updated interim clinical efficacy data including subgroup analyses of first-line pancreatic cancer …
ClinOne Closes Series A Funding Round to Scale its Site and Participant Engagement Platform, Data Driven Insights and Interoperability
April 17, 2023Business Services
BOSTON AND BOULDER, COLO. (PRWEB) APRIL 13, 2023 – ClinOne, the leading provider of Adaptive Experiences in clinical trials announced …
Vaccitech Presents Interim Data from Phase 1b/2 Study of VTP-200 at 35th Annual International Papillomavirus Conference (IPVC) Highlighting Favourable Tolerability and Immunogenicity Profile
April 17, 2023Business Services
OXFORD, United Kingdom, April 17, 2023 (GLOBE NEWSWIRE) – Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company focused on the …
ECCMID 2023: Shionogi Announces Real-World Evidence Demonstrating the Efficacy of Fetcroja (cefiderocol) Against Some of the Most Difficult-to-Treat Gram-Negative Bacterial Pathogens
April 17, 2023Business Services
OSAKA, Japan, APRIL 17, 2023 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; …
PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID
April 17, 2023Business Services
CAMBRIDGE, MA, April 17, 2023 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based …
Companies showcase innovative biotech at American Association for Cancer Research
April 17, 2023Medical Communications
Leading companies in the biotechnology sector will showcase their latest innovations at the American Association for Cancer Research (AACR) meeting …
Complement Therapeutics gains €72m in Series A financing for novel therapeutics research
April 17, 2023Medical Communications
Preclinical stage biotechnology company Complement Therapeutics (CTx) has announced the completion of its Series A financing round, led by Gimv, …
GSK announces positive data from phase 3 trial for new UTI antibiotic
April 17, 2023Research and Development
GSK has shared positive data from its phase 3 trial for gepotidacin as a new oral antibiotic for the treatment …
Merck acquires Prometheus Biosciences, strengthens immunology pipeline
April 17, 2023Sales and Marketing
Merck (known as MSD outside of the US and Canada) has announced that it, through a subsidiary, has agreed to …
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
April 17, 2023Business Services
BOSTON and WILMINGTON, Del. – April 16, 2023 – MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE: …
MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults
April 17, 2023Business Services
Copenhagen, Denmark, 17 April 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group …
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial of Lysergide (LSD) in Major Depressive Disorder (MDD)
April 14, 2023Business Services
NEW YORK, April 14, 2023 — Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical …
Neuromod closes €30m financing for new tinnitus treatment device
April 14, 2023Sales and Marketing
Irish medical device company Neuromod has announced that it has successfully closed a €30m financing intended to further commercialise Lenire, …
Diabeloop announces collaboration with Novo Nordisk for connected diabetes treatment
April 14, 2023Research and Development
Automated insulin delivery company Diabeloop has announced its collaboration with global healthcare company Novo Nordisk, with an agreement which covers …
Merck’s relapsing multiple sclerosis trial put on FDA partial clinical hold over liver injuries
April 14, 2023Research and Development
Merck has announced that its clinical phase 3 study EVOLUTION has been put on partial clinical hold by the FDA …
FDA declines Eli Lilly’s bowel disease drug over manufacturing issues
April 14, 2023Manufacturing and Production
Pharma giant Eli Lilly’s Biologic Licence Application (BLA) for its bowel disease drug has been declined by the FDA over …
UCB’s Rozanolixizumab and Zilucoplan Phase 3 Generalized Myasthenia Gravis studies published in prestigious The Lancet Neurology Journal
April 13, 2023Business Services
Brussels (Belgium) 13 April 2023 – 07:00 AM (CET) – UCB, a global biopharmaceutical company, today announced that The Lancet Neurology …
Adaptyv Bio creates a new paradigm for protein engineering using generative AI, open-source software and synthetic biology
April 13, 2023Business Services
Lausanne, Switzerland – 13th April 2023; AI tools like ChatGPT are revolutionizing how the world generates text, images and code. …
BioInnovation Institute & Science Prize for Innovation winners announced
April 13, 2023Business Services
COPENHAGEN, Denmark, April 13, 2023 – BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, …
Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting
April 13, 2023Sales and Marketing
Copenhagen, Denmark, 13 April, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
